Surfeit locus protein 1 (SURF1) is a protein that in humans is encoded by the SURF1gene.[5][6] The protein encoded by SURF1 is a component of the mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex (MITRAC complex), which is involved in the regulation of cytochrome c oxidase assembly.[7][8] Defects in this gene are a cause of Leigh syndrome, a severe neurological disorder that is commonly associated with systemic cytochrome c oxidase (complex IV) deficiency, and Charcot-Marie-Tooth disease 4K (CMT4K).[9][10]
SURF1 is located on the q arm of chromosome 9 in position 34.2 and has 9 exons.[9] The SURF1 gene produces a 33.3 kDa protein composed of 300 amino acids.[11][12] The protein is a member of the SURF1 family, which includes the related yeast protein SHY1 and rickettsial protein RP733. The gene is located in the surfeit gene cluster, a group of very tightly linked genes that do not share sequence similarity, where it shares a bidirectional promoter with SURF2 on the opposite strand.[9] SURF1 is a multi-pass protein that contains two transmembrane regions, one 19 amino acids in length from positions 61-79 and the other 17 amino acids in length from positions 274–290.[7][8]
This gene encodes a protein localized to the inner mitochondrial membrane and thought to be involved in the biogenesis of the cytochrome c oxidase complex.[9] SURF1 is a multi-pass membrane protein component of the mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex (MITRAC complex). The MITRAC complex regulates cytochrome c oxidase assembly by acting as a central assembly intermediate, receiving subunits imported to the inner mitochondrial membrane and regulating COX1mRNAtranslation.[7][8][13]
Mutations in SURF1 have been associated with mitochondrial complex IV (cytochrome c oxidase) deficiency with clinical manifestations of Leigh syndrome and Charcot-Marie-Tooth disease 4K (CMT4K).[7][8][14]
Charcot-Marie-Tooth disease 4K (CMT4K) is an autosomal recessive, demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention, autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4. CMT4K patients manifest upper and lower limbs involvement. Some affected individuals have nystagmus, polyneuropathy, putaminal and periaqueductal lesions, and late-onset cerebellar ataxia. This disease, when associated with mutations in SURF1, has been found to be linked to cytochrome c oxidase deficiency. Variants associated with this CMT4K have included a homozygous splice site mutation, c.107-2A>G, a missense mutation, c.574C>T, and a deletion, c.799_800del.[10][7][8]
SURF1 has been shown to have 11 binary protein-protein interactions including 8 co-complex interactions. SURF1 interacts with COA3 as part of the mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex (MITRAC complex). PTGES3, SLC25A5, COX6C, COX14, COA1 have all also been found to interact with SURF1.[7][8][16]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Yon J, Jones T, Garson K, Sheer D, Fried M (March 1993). "The organization and conservation of the human Surfeit gene cluster and its localization telomeric to the c-abl and can proto-oncogenes at chromosome band 9q34.1". Human Molecular Genetics. 2 (3): 237–40. doi:10.1093/hmg/2.3.237. PMID8499913.
^Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrette M, Brown GK, Brown RM, Shoubridge EA (December 1998). "SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome". Nature Genetics. 20 (4): 337–43. doi:10.1038/3804. PMID9843204. S2CID12584110.
^ abPéquignot MO, Dey R, Zeviani M, Tiranti V, Godinot C, Poyau A, Sue C, Di Mauro S, Abitbol M, Marsac C (May 2001). "Mutations in the SURF1 gene associated with Leigh syndrome and cytochrome C oxidase deficiency". Human Mutation. 17 (5): 374–81. doi:10.1002/humu.1112. PMID11317352. S2CID26557551.
Shoubridge EA (2001). "Cytochrome c oxidase deficiency". American Journal of Medical Genetics. 106 (1): 46–52. doi:10.1002/ajmg.1378. PMID11579424.
Lennard A, Gaston K, Fried M (November 1994). "The Surf-1 and Surf-2 genes and their essential bidirectional promoter elements are conserved between mouse and human". DNA and Cell Biology. 13 (11): 1117–26. doi:10.1089/dna.1994.13.1117. PMID7702754.
Teraoka M, Yokoyama Y, Ninomiya S, Inoue C, Yamashita S, Seino Y (December 1999). "Two novel mutations of SURF1 in Leigh syndrome with cytochrome c oxidase deficiency". Human Genetics. 105 (6): 560–3. doi:10.1007/s004390051145. PMID10647889.
Poyau A, Buchet K, Bouzidi MF, Zabot MT, Echenne B, Yao J, Shoubridge EA, Godinot C (February 2000). "Missense mutations in SURF1 associated with deficient cytochrome c oxidase assembly in Leigh syndrome patients". Human Genetics. 106 (2): 194–205. doi:10.1007/s004390051028 (inactive 1 November 2024). PMID10746561.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Ogawa Y, Naito E, Ito M, Yokota I, Saijo T, Shinahara K, Kuroda Y (March 2002). "Three novel SURF-1 mutations in Japanese patients with Leigh syndrome". Pediatric Neurology. 26 (3): 196–200. doi:10.1016/S0887-8994(01)00382-4. PMID11955926.
Capková M, Hansíková H, Godinot C, Houst'ková H, Houstĕk J, Zeman J (October 2002). "[A new missense mutation of 574C>T in the SURF1 gene--biochemical and molecular genetic study in seven children with Leigh syndrome]". Casopis Lekaru Ceskych. 141 (20): 636–41. PMID12515039.
Sacconi S, Salviati L, Sue CM, Shanske S, Davidson MM, Bonilla E, Naini AB, De Vivo DC, DiMauro S (February 2003). "Mutation screening in patients with isolated cytochrome c oxidase deficiency". Pediatric Research. 53 (2): 224–30. doi:10.1203/01.PDR.0000048100.91730.6A. hdl:11577/1368344. PMID12538779. S2CID12496207.
Moslemi AR, Tulinius M, Darin N, Aman P, Holme E, Oldfors A (October 2003). "SURF1 gene mutations in three cases with Leigh syndrome and cytochrome c oxidase deficiency". Neurology. 61 (7): 991–3. doi:10.1212/01.wnl.0000082391.98672.0a. PMID14557577. S2CID31028913.
Salviati L, Freehauf C, Sacconi S, DiMauro S, Thoma J, Tsai AC (July 2004). "Novel SURF1 mutation in a child with subacute encephalopathy and without the radiological features of Leigh Syndrome". American Journal of Medical Genetics. Part A. 128A (2): 195–8. doi:10.1002/ajmg.a.30073. hdl:11577/1368341. PMID15214016. S2CID19332655.
Wilnai Y, Seaver LH, Enns GM (September 2012). "Atypical amyoplasia congenita in an infant with Leigh syndrome: a mitochondrial cause of severe contractures?". American Journal of Medical Genetics. Part A. 158A (9): 2353–7. doi:10.1002/ajmg.a.35533. PMID22887355. S2CID1163142.
Timothy J, Geller T (October 2009). "SURF-1 gene mutation associated with leukoencephalopathy in a 2-year-old". Journal of Child Neurology. 24 (10): 1296–301. doi:10.1177/0883073809333543. PMID19805825. S2CID8415901.
van Riesen AK, Antonicka H, Ohlenbusch A, Shoubridge EA, Wilichowski EK (April 2006). "Maternal segmental disomy in Leigh syndrome with cytochrome c oxidase deficiency caused by homozygous SURF1 mutation". Neuropediatrics. 37 (2): 88–94. doi:10.1055/s-2006-924227. PMID16773507. S2CID20192948.
Yüksel A, Seven M, Cetincelik U, Yeşil G, Köksal V (June 2006). "Facial dysmorphism in Leigh syndrome with SURF-1 mutation and COX deficiency". Pediatric Neurology. 34 (6): 486–9. doi:10.1016/j.pediatrneurol.2005.10.020. PMID16765830.
Bruno C, Biancheri R, Garavaglia B, Biedi C, Rossi A, Lamba LD, Bado M, Greco M, Zeviani M, Minetti C (March 2002). "A novel mutation in the SURF1 gene in a child with Leigh disease, peripheral neuropathy, and cytochrome-c oxidase deficiency". Journal of Child Neurology. 17 (3): 233–6. doi:10.1177/088307380201700318. PMID12026244. S2CID27532055.
Williams SL, Taanman JW, Hansíková H, Houst'ková H, Chowdhury S, Zeman J, Houstek J (August 2001). "A novel mutation in SURF1 causes skipping of exon 8 in a patient with cytochrome c oxidase-deficient leigh syndrome and hypertrichosis". Molecular Genetics and Metabolism. 73 (4): 340–3. doi:10.1006/mgme.2001.3206. PMID11509016.
Rahman S, Brown RM, Chong WK, Wilson CJ, Brown GK (June 2001). "A SURF1 gene mutation presenting as isolated leukodystrophy". Annals of Neurology. 49 (6): 797–800. doi:10.1002/ana.1060. PMID11409433. S2CID29980066.
Santoro L, Carrozzo R, Malandrini A, Piemonte F, Patrono C, Villanova M, Tessa A, Palmeri S, Bertini E, Santorelli FM (August 2000). "A novel SURF1 mutation results in Leigh syndrome with peripheral neuropathy caused by cytochrome c oxidase deficiency". Neuromuscular Disorders. 10 (6): 450–3. doi:10.1016/s0960-8966(99)00122-4. PMID10899453. S2CID2885506.